Publications by authors named "Samuel Suzuki"

Claim this Profile
G
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Robert Wesolowski, Hope S Rugo, Jennifer M Specht, Hyo S Han, Peter Kabos, Samuel Suzuki

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, Samuel Suzuki

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, Samuel Suzuki

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
Carol Moreno, Julio Delgado, John C Byrd, William L Zvagelsky, Samuel Suzuki

Br J Haematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, Neil E Kay, Nishitha M Reddy, Samuel Suzuki

Clin Lymphoma Myeloma Leuk· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Paul M Barr, Jennifer R Brown, Peter Hillmen, Susan O'Brien, Jacqueline C Barrientos, Samuel Suzuki

Blood· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
John Fr Robertson, Jean-Marc Ferrero, Hugues Bourgeois, Hagen Kennecke, Richard H de Boer, Samuel Suzuki

Lancet Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis